Randomized Selection Design Trial Evaluating CD8(+)-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

PURPOSE: Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. PATIENTS AND METHODS: Patients with met...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dudley, Mark E., Gross, Colin A., Somerville, Robert P.T., Hong, Young, Schaub, Nicholas P., Rosati, Shannon F., White, Donald E., Nathan, Debbie, Restifo, Nicholas P., Steinberg, Seth M., Wunderlich, John R., Kammula, Udai S., Sherry, Richard M., Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Laurencot, Carolyn M., Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731980/
https://ncbi.nlm.nih.gov/pubmed/23650429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.46.6441
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares